SanguiBioTech GmbH Sustainability Profile
SanguiBioTech GmbH, a pioneering biotechnology firm headquartered in Germany, focuses on innovative solutions in the fields of regenerative medicine and advanced wound care. Founded in 2006, the company has established itself as a leader in developing unique therapeutic products that harness the power of blood-derived biomaterials. With a strong presence in Europe and expanding operations globally, SanguiBioTech is renowned for its flagship product, the SANGUINATE® system, which offers a novel approach to tissue regeneration. This cutting-edge technology distinguishes itself through its ability to enhance healing processes, making it a vital asset in both clinical and surgical settings. SanguiBioTech's commitment to research and development has positioned it as a key player in the biotechnology industry, with notable achievements in product innovation and regulatory approvals, further solidifying its reputation for excellence in healthcare solutions.
DitchCarbon Score
How does SanguiBioTech GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SanguiBioTech GmbH's score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SanguiBioTech GmbH's reported carbon emissions
SanguiBioTech GmbH, headquartered in Germany, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organization. Consequently, there are no documented reduction targets or climate pledges available at this time. As a current subsidiary, SanguiBioTech GmbH may be involved in broader industry initiatives aimed at reducing carbon footprints, but specific commitments or targets have not been disclosed. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In summary, while SanguiBioTech GmbH has not yet provided emissions data or specific climate commitments, its status as a current subsidiary indicates potential for future alignment with industry standards and practices in carbon management.
How Carbon Intensive is SanguiBioTech GmbH's Industry?
How Carbon Intensive is SanguiBioTech GmbH's Location?
SanguiBioTech GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SanguiBioTech GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
